{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["gut microbiota", "inflammatory factor", "psoriasis", "rutaecarpine (RUT)"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38419497", "DateCompleted": {"Year": "2024", "Month": "04", "Day": "03"}, "DateRevised": {"Year": "2024", "Month": "08", "Day": "03"}, "Article": {"Language": ["eng"], "ELocationID": ["10.3724/abbs.2024018"], "ArticleDate": [], "Journal": {"ISSN": "1745-7270", "JournalIssue": {"Volume": "56", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Mar", "Day": "25"}}, "Title": "Acta biochimica et biophysica Sinica", "ISOAbbreviation": "Acta Biochim Biophys Sin (Shanghai)"}, "ArticleTitle": "Rutaecarpine ameliorates imiquimod-induced psoriasis-like dermatitis in mice associated with alterations in the gut microbiota.", "Pagination": {"StartPage": "345", "EndPage": "355", "MedlinePgn": "345-355"}, "Abstract": {"AbstractText": ["Psoriasis is accepted as a chronic, inflammatory, immune-mediated skin disease triggered by complex environmental and genetic factors. For a long time, disease recurrence, drug rejection, and high treatment costs have remained enormous challenges and burdens to patients and clinicians. Natural products with effective immunomodulatory and anti-inflammatory activities from medicinal plants have the potential to combat psoriasis and complications. Herein, an imiquimod (IMQ)-induced psoriasis-like dermatitis model is established in mice. The model mice are treated with 1% rutaecarpine (RUT) (external use) or the oral administration of RUT at different concentrations. Furthermore, high-throughput 16S rRNA gene sequencing is applied to analyze the changes in the diversity and composition of the gut microbiota. Based on the observation of mouse dorsal skin changes, RUT can protect against inflammation to improve psoriasis-like skin damage in mice. Additionally, RUT could suppress the expression levels of proinflammatory cytokines (IL-23, IL-17A, IL-22, IL-6, and IFN-\u03b1) within skin tissue samples. Concerning gut microbiota, we find obvious variations within the composition of gut microflora between IMQ-induced psoriasis mice and RUT-treated psoriasis mice. RUT effectively mediates the recovery of gut microbiota in mice induced by IMQ application. Psoriasis is linked to the production of several inflammatory cytokines and gut microbiome alterations. This research shows that RUT might restore gut microbiota homeostasis, reduce inflammatory cytokine production, and ameliorate psoriasis symptoms. In conclusion, the gut microbiota might be a therapeutic target or biomarker for psoriasis that aids in clinical diagnosis and therapy."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, the Second Affiliated Hospital of South China University, Hengyang 421001, China."}], "LastName": "Li", "ForeName": "Yongjian", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Oncology, Huxiang Cancer Hospital of Traditional Chinese Medicine, Changsha 410205, China."}], "LastName": "Tan", "ForeName": "Zhengping", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, the Second Affiliated Hospital of South China University, Hengyang 421001, China."}], "LastName": "Li", "ForeName": "Wencan", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, the Second Affiliated Hospital of South China University, Hengyang 421001, China."}], "LastName": "Li", "ForeName": "Zongxuan", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, the Second Xiangya Hospital, Central South University, Changsha 410011, China."}], "LastName": "Zhang", "ForeName": "Guiying", "Initials": "G"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Acta Biochim Biophys Sin (Shanghai)", "NlmUniqueID": "101206716", "ISSNLinking": "1672-9145"}, "ChemicalList": [{"RegistryNumber": "P1QW714R7M", "NameOfSubstance": "Imiquimod"}, {"RegistryNumber": "8XZV289PRY", "NameOfSubstance": "rutecarpine"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Ribosomal, 16S"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Indole Alkaloids"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolinones"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Imiquimod"}, {"QualifierName": [], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": ["genetics"], "DescriptorName": "RNA, Ribosomal, 16S"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Psoriasis"}, {"QualifierName": [], "DescriptorName": "Dermatitis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytokines"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Indole Alkaloids"}, {"QualifierName": [], "DescriptorName": "Quinazolinones"}], "CoiStatement": "The authors declare that there are no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. \nLancet. \n. 2021;397:1301\u20131315. doi: 10.1016/S0140-6736(20)32549-6.", "ArticleIdList": ["10.1016/S0140-6736(20)32549-6", "33812489"]}, {"Citation": "Zheng Z, Guo Q, Ma D, Wang X, Zhang C, Wang H, Zhang L, et al.  Related risk factors and treatment management of psoriatic arthritis complicated with cardiovascular disease. \nFront Cardiovasc Med. \n. 2022;9:835439. doi: 10.3389/fcvm.2022.835439.", "ArticleIdList": ["10.3389/fcvm.2022.835439", "PMC9019598", "35463753"]}, {"Citation": "Duvetorp A, Mrowietz U, Nilsson M, Seifert O. Sex and age influence the associated risk of depression in patients with psoriasis: a retrospective population study based on diagnosis and drug-use. \nDermatology. \n. 2021;237:595\u2013602. doi: 10.1159/000509732.", "ArticleIdList": ["10.1159/000509732", "PMC8315676", "32927456"]}, {"Citation": "Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of psoriasis with the risk of developing or dying of cancer. \nJAMA Dermatol. \n. 2019;155:1390\u20131403. doi: 10.1001/jamadermatol.2019.3056.", "ArticleIdList": ["10.1001/jamadermatol.2019.3056", "PMC6802036", "31617868"]}, {"Citation": "Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. \nInt J Mol Sci. \n. 2019;20:1475. doi: 10.3390/ijms20061475.", "ArticleIdList": ["10.3390/ijms20061475", "PMC6471628", "30909615"]}, {"Citation": "Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: a review. \nJ Family Med Prim Care. \n. 2020;9:20\u201324. doi: 10.4103/jfmpc.jfmpc_689_19.", "ArticleIdList": ["10.4103/jfmpc.jfmpc_689_19", "PMC7014874", "32110559"]}, {"Citation": "Ni X, Lai Y. Keratinocyte: a trigger or an executor of psoriasis? \nJ Leukocyte Biol. \n. 2020;108:485\u2013491. doi: 10.1002/JLB.5MR0120-439R.", "ArticleIdList": ["10.1002/JLB.5MR0120-439R", "32170886"]}, {"Citation": "Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. \nJ Dermatol. \n. 2021;48:722\u2013731. doi: 10.1111/1346-8138.15913.", "ArticleIdList": ["10.1111/1346-8138.15913", "33886133"]}, {"Citation": "Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. \nActa Derm Venerol. \n. 2020;100:70\u201380. doi: 10.2340/00015555-3386.", "ArticleIdList": ["10.2340/00015555-3386", "PMC9128930", "31971601"]}, {"Citation": "Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. \nExpert Opin Biol Ther. \n. 2022;22:1431\u20131433. doi: 10.1080/14712598.2022.2113872.", "ArticleIdList": ["10.1080/14712598.2022.2113872", "35968665"]}, {"Citation": "Li X, Ge J, Zheng Q, Zhang J, Sun R, Liu R. Evodiamine and rutaecarpine from\nTetradium ruticarpum in the treatment of liver diseases\n. \nPhytomedicine. \n. 2020;68:153180. doi: 10.1016/j.phymed.2020.153180.", "ArticleIdList": ["10.1016/j.phymed.2020.153180", "32092638"]}, {"Citation": "Byun WS, Bae ES, Kim WK, Lee SK. Antitumor activity of rutaecarpine in human colorectal cancer cells by suppression of Wnt/\u03b2-Catenin signaling. \nJ Nat Prod. \n. 2022;85:1407\u20131418. doi: 10.1021/acs.jnatprod.2c00224.", "ArticleIdList": ["10.1021/acs.jnatprod.2c00224", "35544614"]}, {"Citation": "Tian K, Li J, Xu S. Rutaecarpine: a promising cardiovascular protective alkaloid from\nEvodia rutaecarpa (Wu Zhu Yu)\n. \nPharmacol Res. \n. 2019;141:541\u2013550. doi: 10.1016/j.phrs.2018.12.019.", "ArticleIdList": ["10.1016/j.phrs.2018.12.019", "30616017"]}, {"Citation": "Jia S, Hu C. Pharmacological effects of rutaecarpine as a cardiovascular protective agent. \nMolecules. \n. 2010;15:1873\u20131881. doi: 10.3390/molecules15031873.", "ArticleIdList": ["10.3390/molecules15031873", "PMC6257227", "20336017"]}, {"Citation": "Han M, Hu L, Chen Y. Rutaecarpine may improve neuronal injury, inhibits apoptosis, inflammation and oxidative stress by regulating the expression of ERK1/2 and Nrf2/HO-1 pathway in rats with cerebral ischemia-reperfusion injury. \nDrug Des Devel Ther. \n. 2019;13:2923\u20132931. doi: 10.2147/DDDT.S216156.", "ArticleIdList": ["10.2147/DDDT.S216156", "PMC6708397", "31692511"]}, {"Citation": "Cai QY, Li WR, Wei JJ, Mi SQ, Wang NS. Antinociceptive activity of aqueous and alcohol extract of evodia rutaecarpa.\nIndian J Pharm Sci.  2014, 76: 235\u2013239\n ", "ArticleIdList": ["PMC4090832", "25035536"]}, {"Citation": "Jayakumar T, Yang CM, Yen TL, Hsu CY, Sheu JR, Hsia CW, Manubolu M, et al.  Anti-Inflammatory mechanism of an alkaloid rutaecarpine in LTA-stimulated RAW 264.7 cells: pivotal role on NF-\u03baB and ERK/p38 signaling molecules. \nInt J Mol Sci. \n. 2022;23:5889. doi: 10.3390/ijms23115889.", "ArticleIdList": ["10.3390/ijms23115889", "PMC9180084", "35682568"]}, {"Citation": "Li Z, Yang M, Peng Y, Gao M, Yang B. Rutaecarpine ameliorated sepsis-induced peritoneal resident macrophages apoptosis and inflammation responses. \nLife Sci. \n. 2019;228:11\u201320. doi: 10.1016/j.lfs.2019.01.038.", "ArticleIdList": ["10.1016/j.lfs.2019.01.038", "30690081"]}, {"Citation": "Li Y, Zhang G, Chen M, Tong M, Zhao M, Tang F, Xiao R, et al.  Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-\u03baB and TLR7 pathways in mice. \nBiomed Pharmacother. \n. 2019;109:1876\u20131883. doi: 10.1016/j.biopha.2018.10.062.", "ArticleIdList": ["10.1016/j.biopha.2018.10.062", "30551443"]}, {"Citation": "Okada K, Matsushima Y, Mizutani K, Yamanaka K. The role of gut microbiome in psoriasis: oral administration of\nStaphylococcus aureus and\nStreptococcus danieliae exacerbates skin inflammation of imiquimod-induced psoriasis-like dermatitis\n. \nInt J Mol Sci. \n. 2020;21:3303. doi: 10.3390/ijms21093303.", "ArticleIdList": ["10.3390/ijms21093303", "PMC7246652", "32392785"]}, {"Citation": "Soare A, Weber S, Maul L, Rauber S, Gheorghiu AM, Luber M, Houssni I, et al.  Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. \nJ Immunol. \n. 2018;200:1249\u20131254. doi: 10.4049/jimmunol.1700596.", "ArticleIdList": ["10.4049/jimmunol.1700596", "29330320"]}, {"Citation": "Wells JM, Brummer RJ, Derrien M, MacDonald TT, Troost F, Cani PD, Theodorou V, et al.  Homeostasis of the gut barrier and potential biomarkers. \nAm J Physiol Gastrointestinal Liver Physiol. \n. 2017;312:G171\u2013G193. doi: 10.1152/ajpgi.00048.2015.", "ArticleIdList": ["10.1152/ajpgi.00048.2015", "PMC5440615", "27908847"]}, {"Citation": "Martinez-Lopez M, Iborra S, Conde-Garrosa R, Mastrangelo A, Danne C, Mann ER, Reid DM, et al.  Microbiota sensing by mincle-syk axis in dendritic cells regulates interleukin-17 and -22 production and promotes intestinal barrier integrity. \nImmunity. \n. 2019;50:446\u2013461.e9. doi: 10.1016/j.immuni.2018.12.020.", "ArticleIdList": ["10.1016/j.immuni.2018.12.020", "PMC6382412", "30709742"]}, {"Citation": "Wang LY, Yeh SL, Hsu ST, Chen CH, Chen CC, Chuang CH. The anti-proliferative and apoptotic effects of rutaecarpine on human esophageal squamous cell carcinoma cell line CE81T/VGH\nin vitro and\nin vivo\n. \nInt J Mol Sci. \n. 2022;23:2843. doi: 10.3390/ijms23052843.", "ArticleIdList": ["10.3390/ijms23052843", "PMC8911365", "35269987"]}, {"Citation": "Zhang Y, Yan T, Sun D, Xie C, Wang T, Liu X, Wang J, et al.  Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced colitis. \nFree Radical Biol Med. \n. 2020;148:33\u201341. doi: 10.1016/j.freeradbiomed.2019.12.012.", "ArticleIdList": ["10.1016/j.freeradbiomed.2019.12.012", "PMC7376370", "31874248"]}, {"Citation": "Zhu QN, Zhang D, Jin T, Wu Q, Liu J, Lu YF. Rutaecarpine effects on expression of hepatic phase-1, phase-2 metabolism and transporter genes as a basis of herb\u2013drug interactions. \nJ Ethnopharmacol. \n. 2013;147:215\u2013219. doi: 10.1016/j.jep.2013.03.005.", "ArticleIdList": ["10.1016/j.jep.2013.03.005", "23510861"]}, {"Citation": "Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, et al.  QIIME allows analysis of high-throughput community sequencing data. \nNat Methods. \n. 2010;7:335\u2013336. doi: 10.1038/nmeth.f.303.", "ArticleIdList": ["10.1038/nmeth.f.303", "PMC3156573", "20383131"]}, {"Citation": "Vi\u010di\u0107 M, Ka\u0161telan M, Brajac I, Soto\u0161ek V, Massari LP. Current concepts of psoriasis immunopathogenesis. \nInt J Mol Sci. \n. 2021;22:11574. doi: 10.3390/ijms222111574.", "ArticleIdList": ["10.3390/ijms222111574", "PMC8584028", "34769005"]}, {"Citation": "Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? \nBr J Dermatol. \n. 2020;182:840\u2013848. doi: 10.1111/bjd.18245.", "ArticleIdList": ["10.1111/bjd.18245", "PMC7187293", "31225638"]}, {"Citation": "Buha\u0219 MC, Gavrila\u0219 LI, Candrea R, C\u0103tinean A, Mocan A, Miere D, T\u0103taru A. Gut microbiota in psoriasis. \nNutrients. \n. 2022;14:2970. doi: 10.3390/nu14142970.", "ArticleIdList": ["10.3390/nu14142970", "PMC9321451", "35889927"]}, {"Citation": "Zhang X, Shi L, Sun T, Guo K, Geng S. Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients. \nBMC Microbiol. \n. 2021;21:78. doi: 10.1186/s12866-021-02125-1.", "ArticleIdList": ["10.1186/s12866-021-02125-1", "PMC7941898", "33685393"]}, {"Citation": "Kamada N, Seo SU, Chen GY, N\u00fa\u00f1ez G. Role of the gut microbiota in immunity and inflammatory disease. \nNat Rev Immunol. \n. 2013;13:321\u2013335. doi: 10.1038/nri3430.", "ArticleIdList": ["10.1038/nri3430", "23618829"]}, {"Citation": "Muromoto R, Hirao T, Tawa K, Hirashima K, Kon S, Kitai Y, Matsuda T. IL-17A plays a central role in the expression of psoriasis signature genes through the induction of I\u03baB-\u03b6 in keratinocytes. \nInt Immunol. \n. 2016;28:443\u2013452. doi: 10.1093/intimm/dxw011.", "ArticleIdList": ["10.1093/intimm/dxw011", "26944069"]}, {"Citation": "Lochner M, Wang Z, Sparwasser T. The special relationship in the development and function of T helper 17 and regulatory T cells.\nProg Mol Biol Transl Sci.  2015, 136: 99\u2013129\n ", "ArticleIdList": ["26615094"]}, {"Citation": "Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, et al.  The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. \nScience. \n. 2013;341:569\u2013573. doi: 10.1126/science.1241165.", "ArticleIdList": ["10.1126/science.1241165", "PMC3807819", "23828891"]}, {"Citation": "Tan LR, Zhao S, Zhu W, Wu L, Li J, Shen MX, Lei L, et al.  The\nAkkermansia muciniphila is a gut microbiota signature in psoriasis\n. \nExp Dermatol. \n. 2018;27:144\u2013149. doi: 10.1111/exd.13463.", "ArticleIdList": ["10.1111/exd.13463", "29130553"]}, {"Citation": "Hidalgo-Cantabrana C, Gomez J, Delgado S, Requena-Lopez S, Queiro-Silva R, Margolles A, Coto E, et al.  Gut microbiota dysbiosis in a cohort of patients with psoriasis. \nBr J Dermatol. \n. 2019;181:1287\u20131295. doi: 10.1111/bjd.17931.", "ArticleIdList": ["10.1111/bjd.17931", "30920647"]}, {"Citation": "Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease. \nJAMA Dermatol. \n. 2018;154:1417\u20131423. doi: 10.1001/jamadermatol.2018.3631.", "ArticleIdList": ["10.1001/jamadermatol.2018.3631", "PMC6583370", "30422277"]}, {"Citation": "Chen YJ, Ho HJ, Tseng CH, Lai ZL, Shieh JJ, Wu CY. Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients. \nExp Dermatol. \n. 2018;27:1336\u20131343. doi: 10.1111/exd.13786.", "ArticleIdList": ["10.1111/exd.13786", "30238519"]}, {"Citation": "Chang HW, Yan D, Singh R, Liu J, Lu X, Ucmak D, Lee K, et al.  Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. \nMicrobiome. \n. 2018;6:154. doi: 10.1186/s40168-018-0533-1.", "ArticleIdList": ["10.1186/s40168-018-0533-1", "PMC6125946", "30185226"]}, {"Citation": "Chen HL, Zeng YB, Zhang ZY, Kong CY, Zhang SL, Li ZM, Huang JT, et al.  Gut and cutaneous microbiome featuring abundance of lactobacillus reuteri protected against psoriasis-like inflammation in mice. \nJ Inflamm Res. \n. 2021:6175\u20136190. doi: 10.2147/JIR.S337031.", "ArticleIdList": ["10.2147/JIR.S337031", "PMC8627893", "34853526"]}, {"Citation": "Chen YH, Wu CS, Chao YH, Lin CC, Tsai HY, Li YR, Chen YZ, et al.  Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. \nJ Food Drug Anal. \n. 2017;25:559\u2013566. doi: 10.1016/j.jfda.2016.06.003.", "ArticleIdList": ["10.1016/j.jfda.2016.06.003", "PMC9328808", "28911642"]}, {"Citation": "Dziarski R, Park SY, Kashyap DR, Dowd SE, Gupta D. Pglyrp-regulated gut microflora\nPrevotella falsenii, Parabacteroides distasonis and\nBacteroides eggerthii enhance and\nAlistipes finegoldii attenuates colitis in mice.\nPLoS One.  2016, 11: e0146162\n ", "ArticleIdList": ["PMC4699708", "26727498"]}, {"Citation": "Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, et al.  Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. \nScience. \n. 2013;342:967\u2013970. doi: 10.1126/science.1240527.", "ArticleIdList": ["10.1126/science.1240527", "PMC6709532", "24264989"]}, {"Citation": "Yoshida N, Yamashita T, Hirata K. Gut microbiome and cardiovascular diseases. \nDiseases. \n. 2018;6:56. doi: 10.3390/diseases6030056.", "ArticleIdList": ["10.3390/diseases6030056", "PMC6164700", "29966270"]}, {"Citation": "Hevia A, Milani C, Lopez P, Cuervo A, Arboleya S, Duranti S, Turroni F,\net al. Intestinal dysbiosis associated with systemic lupus erythematosus.\nmBio.  2014, 5: e01548\u201301514\n ", "ArticleIdList": ["PMC4196225", "25271284"]}, {"Citation": "Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE, Reider SJ, Hackl H, et al.  Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. \nCell Host Microbe. \n. 2016;19:455\u2013469. doi: 10.1016/j.chom.2016.03.007.", "ArticleIdList": ["10.1016/j.chom.2016.03.007", "27078067"]}, {"Citation": "Olejniczak-Staruch I, Ci\u0105\u017cy\u0144ska M, Sobolewska-Sztychny D, Narbutt J, Skibi\u0144ska M, Lesiak A. Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis. \nInt J Mol Sci. \n. 2021;22:3998. doi: 10.3390/ijms22083998.", "ArticleIdList": ["10.3390/ijms22083998", "PMC8069836", "33924414"]}, {"Citation": "Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A, Olszewska M, et al.  Gut microbiome in psoriasis: an updated review. \nPathogens. \n. 2020;9:463. doi: 10.3390/pathogens9060463.", "ArticleIdList": ["10.3390/pathogens9060463", "PMC7350295", "32545459"]}, {"Citation": "Thye AYK, Bah YR, Law JWF, Tan LTH, He YW, Wong SH, Thurairajasingam S, et al.  Gut-Skin axis: unravelling the connection between the gut microbiome and psoriasis. \nBiomedicines. \n. 2022;10:1037. doi: 10.3390/biomedicines10051037.", "ArticleIdList": ["10.3390/biomedicines10051037", "PMC9138548", "35625774"]}]}], "History": [{"Year": "2024", "Month": "4", "Day": "3", "Hour": "6", "Minute": "44"}, {"Year": "2024", "Month": "2", "Day": "29", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "2", "Day": "29", "Hour": "3", "Minute": "16"}, {"Year": "2024", "Month": "2", "Day": "28"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38419497", "PMC11292129", "10.3724/abbs.2024018"]}}]}